MedTrace Logo

Danish Prostate Cancer Consortium Study-1

NCT05767307 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2023-11-29

No results posted yet for this study

Summary

The purpose of the study is to investigate if a new promising microRNA-based urine biomarker test for prostate cancer, called uCaP, is better than the current standard test (PSA) to identify men who would benefit from an MRI scan of the prostate. The study will include 2,500 men referred to MRI of the prostate at three major hospital centers in Denmark (Aarhus, Odense, and Herlev) and compare the accuracy of uCaP to PSA. Based on preliminary data it is expected that uCaP will be \>20% better than PSA at identifying treatment-requiring cancer. Hence, uCaP could help to better pre-select men for MRI and thereby reduce unnecessary MRI scans, unnecessary prostate biopsies, as well as overdiagnosis and overtreatment of indolent PCs, while maintaining high sensitivity for aggressive PC that needs early detection and early treatment.

Conditions

Sponsors & Collaborators

  • University of Aarhus

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • Herlev and Gentofte Hospital

    collaborator OTHER

  • Aarhus University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2025-12-31
Completion
2040-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05767307 on ClinicalTrials.gov